TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00528619
Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg\*min/mL until progression or unacceptable toxicity.
Study: NCT00990795
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
Study: NCT00990795
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
Study: NCT03435692
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the operating room patients, intravenous morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and after fentanyl had been administered. Intravenous Morphine was also administered in the operating room if the patient was randomized to the Patient Controlled Analgesia (PCA) arm of the study. Post operatively intravenous Morphine was administered as needed for severe pain.
Study: NCT03435692
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Lorazepam was administered as needed for muscle spasm post operatively.
Study: NCT03435692
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ondansetron was administered as needed for nausea and vomiting post operatively.
Study: NCT03435692
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Diphenhydramine was administered as needed for itching postoperatively.
Study: NCT03435692
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Oxycodone was administered as needed for breakthrough pain post operatively.
Study: NCT03435692
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
Study: NCT00821587
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
Study: NCT00821587
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
Study: NCT01597609
Drug: sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg, taken orally once per day for 12 weeks
Study: NCT03134378
Drug: Rabeprazole Sodium 20mg
Normalized name: Rabeprazole Sodium 20mg Oral tablet, gastro-resistant
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03134378
Drug: Amoxicillin 500 Mg
Normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily
Study: NCT02182050
Drug: BIBF 1120 ES low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02745353
Drug: naloxegol
Normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02774265
Drug: VTE prophylaxis with Enoxaparin 30mg BID
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
Study: NCT02774265
Drug: VTE prophylaxis with Aspirin 81mg BID
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
Study: NCT02781090
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants, in both study arms, will be offered a 3-month supply of nicotine patches
Study: NCT00913848
Drug: Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
Normalized name: valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913848
Drug: Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Normalized name: divalproex sodium 500 MG [Depakote]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03390582
Drug: Methimazole Pill
Normalized name: methimazole Pill
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
Study: NCT01254305
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
Study: NCT01208103
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given CVC
Study: NCT02726399
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
Study: NCT02726399
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
Study: NCT01766115
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HCV Protease Inhibitor
Study: NCT02726399
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80mg/m2 administered as an IV infusion every 21 days
Study: NCT00573950
Drug: cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
Study: NCT02551653
Drug: [11C]-GSK2256098 500 MBq
DrugBank: GSK2256098 (DB16106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
Study: NCT00418548
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00451724
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03361605
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration
Study: NCT00162916
Drug: citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg or 40mg, once daily, for 40 weeks
Study: NCT04037657
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
Study: NCT00912821
Drug: 6 L dialysate
Normalized name: 6-ammonio-L-norleucine
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 L peritoneal dialysis solution
Study: NCT00912821
Drug: 8 L dialysate
Normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 L peritoneal dialysis solution
Study: NCT01644084
Drug: Hydroxyethyl starch 130/0.4
Normalized name: Hydroxyethyl starch 130/0.4
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
Study: NCT02449551
Drug: Volitinib
Normalized name: Volitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
Study: NCT00980109
Drug: active oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
Study: NCT01158079
Drug: ALN-VSP02
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
Study: NCT01641159
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
Study: NCT00436605
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00980109
Drug: zanamivir for inhalation
Normalized name: zanamivir Inhalant Product
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
Study: NCT00695682
Drug: intravitreal injection of infliximab
Normalized name: infliximab Injection
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
Study: NCT02580773
Drug: Prophylactic anticoagulation ( INNOHEP®)
Normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
Study: NCT02580773
Drug: Curative anticoagulation ( INNOHEP®)
Normalized name: tinzaparin sodium Injectable Solution [Innohep]
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
Study: NCT01907074
Drug: Cholates
Normalized name: cholate
DrugBank: Berberine ursodeoxycholate (DB18111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholates is given intravenously (IV push) and by mouth, once per study visit
Study: NCT04438096
Drug: 300 mg
Normalized name: rutin 300 MG
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 100 mg pills (QD) will be orally administered for 12 weeks
Study: NCT00433576
Drug: resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02199223
Drug: regorafenib + panitumumab
Normalized name: Regorafenib
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00297505
Drug: citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01594775
Drug: Syntocinon (Oxytocin) nasal spray
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
Study: NCT00886795
Drug: abatacept (Orencia ®)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
Study: NCT02837003
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Study: NCT02837003
Drug: Thienopyridine
Normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Study: NCT01217177
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00853944
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
Study: NCT00163280
Drug: ATL-104
Normalized name: ATL-104
DrugBank: ATL-104 (DB05670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
Study: NCT01208649
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
Study: NCT00571467
Drug: PRTX-100 (Staphylococcal protein A)
Normalized name: Protein-type A microspheres
DrugBank: PRTX-100 (DB05947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~* Cohort 1: 0.075 mcg/kg~* Cohort 2: 0.15 mcg/kg~* Cohort 3: 0.30 mcg/kg
Study: NCT00818779
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 - 300 mg once daily for 6 weeks
Study: NCT00818779
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 mg once daily for 6 weeks
Study: NCT01592695
Drug: Nicotine replacement therapy - transdermal nicotine patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study: NCT01592695
Drug: Nicotine replacement therapy - nicotine gum
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01592695
Drug: Nicotine replacement therapy - nicotine lozenge
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01592695
Drug: Bupropion Sustained Release
Normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01592695
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01592695
Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01592695
Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01518153
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m\^2 by vein on Day -6 to -3.
Study: NCT01518153
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m\^2 by vein on Day -2.
Study: NCT01592695
Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01518153
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg by vein on Day -1.
Study: NCT01518153
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
Study: NCT01518153
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
Study: NCT02421575
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00229138
Drug: EC-MPS, Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03775928
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib 425mg qd po
Study: NCT01632540
Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Normalized name: beclomethasone dipropionate Nasal Product
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
Study: NCT00644670
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
Study: NCT00644670
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
Study: NCT02766673
Drug: Albuterol Sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Study: NCT03376555
Drug: Local Heating (LH)
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin
Study: NCT02870829
Drug: menaquinone-7
Normalized name: menaquinone-7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement given post dialysis 3x/week
Study: NCT03376555
Drug: Flow Mediated Dilation with nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.